



US 20120207752A1

(19) **United States**(12) **Patent Application Publication**
Chackerian et al.(10) **Pub. No.: US 2012/0207752 A1**(43) **Pub. Date: Aug. 16, 2012**(54) **METHODS FOR MODULATING IL-33
ACTIVITY**(75) Inventors: **Alissa A. Chackerian**, Sunnyvale,
CA (US); **Robert A. Kastelein**,
Portola Valley, CA (US)(73) Assignee: **Schering Corporation**, Rahway, NJ
(US)(21) Appl. No.: **13/456,071**(22) Filed: **Apr. 25, 2012****Related U.S. Application Data**(60) Continuation of application No. 12/501,870, filed on
Jul. 13, 2009, now Pat. No. 8,187,596, which is a
division of application No. 11/779,755, filed on Jul.
18, 2007, now Pat. No. 7,560,530.(60) Provisional application No. 60/887,257, filed on Jan.
30, 2007, provisional application No. 60/835,250,
filed on Aug. 3, 2006, provisional application No.
60/832,256, filed on Jul. 20, 2006.**Publication Classification**(51) **Int. Cl.**

<i>A61K 39/395</i>	(2006.01)
<i>G01N 33/53</i>	(2006.01)
<i>A61P 35/00</i>	(2006.01)
<i>A61P 25/00</i>	(2006.01)
<i>A61P 19/02</i>	(2006.01)
<i>A61P 11/06</i>	(2006.01)
<i>A61P 37/08</i>	(2006.01)
<i>A61P 27/02</i>	(2006.01)
<i>A61P 29/00</i>	(2006.01)
<i>A61P 31/04</i>	(2006.01)
<i>A61P 33/00</i>	(2006.01)
<i>A61P 31/12</i>	(2006.01)
<i>A61P 33/02</i>	(2006.01)
<i>A61P 33/12</i>	(2006.01)
<i>C07K 17/02</i>	(2006.01)

(52) **U.S. Cl.** **424/133.1**; 424/158.1; 530/350;
530/351; 424/172.1; 435/7.1; 436/501

(57)

ABSTRACTProvided herein are methods of modulating IL-33 activity,
e.g., for the purpose of treating immune diseases and condi-
tions, as well as methods of screening for compounds capable
antagonizing IL-33 signaling.




Figure 1A




Figure 1B




Figure 2A




Figure 2B




Figure 3




Figure 4A




Figure 4B




Figure 4C




Figure 4D




Figure 4E




Figure 4F

IL-33-induced IL-6 production from WTMCs




Figure 5




Figure 6




Figure 7A




Figure 7B




Figure 7C




Figure 8A




Figure 8B




Figure 9

METHODS FOR MODULATING IL-33 ACTIVITY

[0001] This application is a Continuation of U.S. patent application Ser. No. 12/501,870, filed on Jul. 13, 2009, which is a Divisional of U.S. patent application Ser. No. 11/779,755, filed on Jul. 18, 2007, now U.S. Pat. No. 7,560,530, issued Jul. 14, 2009, which claims benefit of U.S. Provisional Patent Application Nos. 60/832,256 (filed Jul. 20, 2006), 60/835,250 (filed Aug. 3, 2006), and 60/887,257 (filed Jan. 30, 2007), each of which is hereby incorporated by reference in their entireties.

[0002] The Sequence Listing filed electronically herewith is also hereby incorporated by reference in its entirety (File Name: BP06497-US-CNT_SeqListing.txt; Date Created: Apr. 24, 2012; File Size: 18.2 KB.)

FIELD OF THE INVENTION

[0003] The present invention relates to methods for modulating IL-33 activity.

BACKGROUND OF THE INVENTION

[0004] The immune system protects individuals from infective agents, e.g., bacteria, multi-cellular organisms, as well as cancers. This system includes several types of lymphoid and myeloid cells such as monocytes, macrophages, dendritic cells (DCs), eosinophils, T cells, B cells, and neutrophils. These lymphoid and myeloid cells often produce signaling proteins known as cytokines. Immune response includes inflammation, i.e., the accumulation of immune cells systemically or in a particular location of the body. In response to an infective agent or foreign substance, immune cells secrete cytokines which, in turn, modulate immune cell proliferation, development, differentiation, or migration. Immune response sometimes results in pathological consequences, that is, inflammatory disorders. These inflammatory disorders, which involve immune cells and cytokines, include, e.g., psoriasis, rheumatoid arthritis (RA), Crohn's disease (CD), multiple sclerosis (MS), and atherosclerosis.

[0005] The interleukin-1 (IL-1) family of cytokines contributes to the pathology of inflammatory disorders and proliferative conditions, e.g., arthritis and cancer. There are 11 members of the IL-1 cytokine family. IL-1 cytokines bind to members of the IL-1 cytokine receptor family. There are ten members in the IL-1 receptor family, and IL-1 ligands typically require participation of two different IL-1 receptors to make up the cell surface complex. For example, IL-1 α and IL-1 β bind first to the cell surface receptor IL-1R1, and this IL-1/IL-1R1 complex subsequently binds to a second cell surface IL-1R family member, IL-1 Receptor accessory chain protein (IL-1RAcP). Binding of IL-1 α or IL-1 β to both receptor components is necessary to transduce the IL-1 signal.

[0006] IL-1 family members play a role in inflammatory conditions, e.g., rheumatoid arthritis, psoriasis, asthma, chronic obstructive pulmonary disorder (COPD), sepsis, and inflammatory bowel disorder (IBD). Rheumatoid arthritis (RA) is a common chronic inflammatory disorder characterized by degradation of joints, e.g., the synovial membrane, cartilage, and bone. IL-1 stimulates a number of cells involved in arthritic inflammation, e.g., fibroblasts, osteo-

clasts, chondrocytes, and neutrophils, which may show abnormal proliferation and release enzymes causing joint destruction.

[0007] Proliferative disorders are the second most common cause of death in the United States. Cytokines of the IL-1 family have been implicated in the control and pathology of proliferative disorders, i.e., cancer. IL-1 modulates progression through the cell cycle, e.g., by changing expression of cyclin-dependent kinases and cyclin-dependent kinase inhibitors. High doses of IL-1 β promote tumor invasiveness, while low doses can promote immune eradication of tumors.

[0008] IL-33 exerts its biological effects via the receptor protein ST2 and induces T Helper Type 2-associated cytokines (Schmitz, J. et al., *Immunity* 23: 479-490 (2005)). In cells stimulated with IL-33, the signaling components MyD88, IRAK, IRAK4 and TRAF6 are recruited to ST2. In addition, IL-33 mediated signaling involves phosphorylation of I κ B α and phosphorylation of the MAP kinases Erk1/2, p38 and JNK. T_H2 cells, but not T_H1 cells, respond to IL-33 stimulation with increased production of IL-5 and IL-13. IL-33 administration results in splenomegaly with significantly higher numbers of spleen eosinophils, mononuclear cells, and plasma cells, but not neutrophils. IL-33 administration also results in increased levels of blood eosinophils, lymphocytes and neutrophils. IL-33 administration also leads to induction of IL-4, IL-5 and IL-13 gene and protein expression in vivo. IL-33 administration also results in airway epithelial lining hypertrophy and mucous production, epithelial hyperplasia in the esophagus, and inflammatory infiltrates of eosinophils, neutrophils and mononuclear cells in the esophageal epithelium. In addition, IL-33 administration results in increased levels of serum IgE and IgA.

[0009] There remains an unmet need to treat inflammatory and immune disorders. Specifically, the need exists for improved compositions and methods of treatment for immune disorders related to IL-33 signaling in which reduction of IL-33 activity would provide therapeutic benefit.

SUMMARY OF THE INVENTION

[0010] We have previously shown that the orphan receptor ST2 is one of the components of the IL-33 receptor complex (Schmitz, J. et al., *Immunity* 23: 479-490 (2005)). It was thought that the receptor complex that binds IL-33 is a complex of ST2 and SIGIRR. See WO 2005/079844. Here, we explain that the second component of the IL-33 receptor complex is not SIGIRR, but is instead IL-1RAcP. Although no receptor promiscuity has been observed for the major IL-1 ligands (IL-1 α and IL-1 β exclusively bind to IL-1R1 and IL-1RAcP, and IL-18 binds exclusively to IL-18R α and IL-18R β), we focused on IL-1RAcP after we were unsuccessful in finding the second IL-33 receptor among the orphan IL-1 receptors. Accordingly, the present invention provides that IL-33 signal transduction occurs through ST2 and IL-1RAcP.

[0011] In one aspect, the present invention provides methods of modulating (e.g. preventing, reducing or ameliorating) an immune disorder or condition, comprising inhibiting IL-33 signal transduction through ST2 and IL-1RAcP by administering to a subject in need thereof an effective amount of: (a) an antagonist of IL-33 binding to a complex of ST2 and IL-1RAcP, and/or (b) an antagonist of IL-1RAcP binding to a complex of IL-33 and ST2.

[0012] The present invention also provides methods of modulating blood cell counts, comprising inhibiting IL-33

signal transduction through ST2 and IL-1RAcP by administering to a subject in need thereof an effective amount of: (a) an antagonist of IL-33 binding to a complex of ST2 and IL-1RAcP, and/or (b) an antagonist of IL-1RAcP binding to a complex of IL-33 and ST2. Such modulation, e.g. may include increasing the count of platelets and/or decreasing the counts of one or more of total white blood cells, neutrophils, lymphocytes and eosinophils.

[0013] In various embodiments the antagonist comprises an antibody, or antigen-binding fragment thereof, that binds to IL-33, ST2, or a complex of IL-33 bound to ST2.

[0014] In other embodiments, the antagonist comprises an antibody, or antigen-binding fragment thereof, that binds to IL-1RAcP, a complex of IL-1RAcP and ST2, or a complex of IL-1RAcP, ST2 and IL-33. In some embodiments the antibody or fragment does not bind to IL-33 alone and/or does not bind to ST2 alone.

[0015] In yet another embodiment, the antibody or fragment does not bind to IL-1RAcP alone.

[0016] In one embodiment, the antibody or fragment thereof is a monoclonal, humanized, or fully human antibody. In another embodiment, the antibody or fragment is an Fab, an Fv fragment, or an F(ab')₂ fragment.

[0017] In some embodiments, the immune disorder or condition is selected from the group consisting of an innate response, asthma, an allergy, multiple sclerosis, inflammatory bowel disorder, arthritis, an infection, cancer, and a tumor. Exemplary arthritic conditions may be selected from the group consisting of rheumatoid arthritis, osteoarthritis, and psoriatic arthritis. Exemplary infections may be selected from the group consisting of an intracellular pathogen, a bacterium, a parasite and a virus. Exemplary intracellular pathogens may be selected from the group consisting of *Leishmania* sp., *Mycobacterium* sp., *Listeria* sp., *Toxoplasma* sp., *Schistosoma* sp.

[0018] In other embodiments, the immune disorder or condition is a T_H1-type response or a T_H2-type response.

[0019] In another aspect, the present invention provides methods and kits for the diagnosis of an immune condition or disorder. In one embodiment, the diagnostic method comprises determining the presence or level of one or more of IL-33, ST2, IL-1RAcP, a complex of IL-33 and ST2, a complex of ST2 and IL-1RAcP and a complex of ST2, IL-1RAcP and IL-33 in a sample from a subject, and comparing that level to the levels in non-diseased tissues, subjects that are known to have the immune condition or disorder, and/or subjects that are known not to have the immune condition or disorder. In one embodiment, the presence or level of a complex of IL-33 and ST2 is detected. In one embodiment the detection involves use of a binding compound comprising a detectable label, e.g. an antibody or antigen-binding fragment thereof. In another embodiment, the invention involves kits to perform the diagnostic methods of the invention, comprising: a compartment; a detectably-labeled molecule, such as an antibody, that binds one or more of IL-33, ST2, IL-1RAcP, a complex of IL-33 and ST2, a complex of ST2 and IL-1RAcP and a complex of ST2, IL-1RAcP and IL-33; and, optionally, instructions for use. In one embodiment, the detectably-labeled molecule binds to a complex of IL-33 and ST2.

[0020] In another aspect, the present invention provides an isolated and purified complex of ST2 and IL-1RAcP, optionally further comprising IL-33, and sequence variants thereof. In one embodiment the ST2, IL-1RAcP and IL-33 are human proteins. In other embodiments, the invention provides such

complexes comprising polypeptide having 70%, 80%, 90%, 95%, 98% or 100% sequence identity with a naturally occurring human ST2, IL-1RAcP or IL-33 protein. In one aspect, the invention provides methods of making these isolated and purified complexes, comprising mixing two or more of the proteins and allowing said complex to form.

[0021] In yet another aspect, the present invention provides in vitro methods of determining whether a test compound is an antagonist of IL-33 binding to a complex of ST2 and IL-1RAcP, and/or IL-1RAcP binding to a complex of IL-33 and ST2, comprising an assay selected from the group consisting of a) an NF-κB-dependent reporter gene expression assay, b) an MyD88 IRAK, IRAK4 or TRAF6 recruitment assay, c) an Erk1/2, p38, IκBα or JNK phosphorylation assay, d) an NF-κB, Erk1/2 or p38 phosphorylation assay in cells that naturally express ST2, e) an IL-13, IL-6 or IL-5 expression assay, and f) an IL-6 production assay in mouse mast cell line WTMC. In some embodiments, the test compound is determined to be an antagonist if it reduces the activity of IL-33 in the assay when compared to an assay run without the test compound.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] FIG. 1 shows that IL-33 administration increases the percentage of eosinophils found in the blood of wild-type (WT) mice, but not IL-1RAcP deficient (KO) mice. Individual data bars represent separate experimental animals, with one experiment involving five animals (FIG. 1A) and another involving three animals (FIG. 1B).

[0023] FIG. 2 shows that IL-33 administration increases IL-5 production in serum (FIG. 2A) and bronchoalveolar lavage (BAL) (FIG. 2B) in wild-type (WT) mice, but not in IL-1RAcP deficient (KO) mice.

[0024] FIG. 3 shows that IL-33 administration increases serum IgE in wild-type (WT) mice, but not in IL-1RAcP deficient (KO) mice.

[0025] FIGS. 4A-4F show that, unlike wild-type (WT) mice, IL-1RAcP deficient (KO) mice do not upregulate T_H2 cytokine or cytokine receptor genes in response to IL-33 administration.

[0026] FIG. 5 shows that IL-33 induces IL-6 production from WTMC cells in a dose dependent manner.

[0027] FIG. 6 shows that blocking ST2 prevents IL-33-induced IL-6 production in WTMC cells.

[0028] FIG. 7 shows that IL-1RAcP is necessary for IL-33-enhanced IL-13 (FIG. 7A), IL-6 (FIG. 7B), and IL-5 (FIG. 7C) production from T_H2 cells.

[0029] FIG. 8 shows the detection of the ST2/IL-33/IL-1RAcP complex, in which ST2 is immobilized on the plate in FIG. 8A and IL-1R1 is immobilized on the plate in FIG. 8B.

[0030] FIG. 9 shows that dominant negative IL-1RAcP inhibits IL-33 signaling.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] As used herein, including the appended claims, the singular forms of words such as “a,” “an,” and “the,” include their corresponding plural references unless the context clearly dictates otherwise.

[0032] “Administering” refers to the delivery to an animal, human, subject, cell, tissue, organ, or biological fluid of an exogenous composition, pharmaceutical, therapeutic, or diagnostic agent, e.g. an agent containing an antagonist of

IL-33 signal transduction through ST2 and IL-1RAcP. In one embodiment, “administering” refers to delivery to a subject. In another embodiment, “administering” refers to delivery to a human subject.

[0033] An “antagonist of IL-33 binding to a complex of ST2 and IL-1RAcP” is a molecule that inhibits IL-33 binding to a complex of ST2 and IL-1RAcP. An “antagonist of IL-1RAcP binding to a complex of IL-33 and ST2” is a molecule that inhibits binding of IL-1RAcP to a complex of IL-33 and ST2. In one embodiment, the antagonist is an antibody, such as a polyclonal antibody, a monoclonal antibody, a humanized antibody, or a human antibody. In another embodiment, the antagonist is an antibody fragment, such as a Fab, an Fv fragment, or a F(ab')₂ fragment.

[0034] In another embodiment, the antibody or fragment thereof specifically binds to (a) IL-33, (b) IL-1RAcP, (c) ST2, (d) a complex of ST2 bound to IL-1RAcP, (e) a complex of IL-33 bound to ST2, or (f) a complex of IL-33, ST2 and IL-1RAcP.

[0035] In one embodiment, an “effective amount” of the antagonist of IL-33 signal transduction through ST2 and IL-1RAcP means an amount sufficient to ameliorate a symptom or sign of a disorder or physiological condition, or an amount sufficient to permit or facilitate the diagnosis of a disorder or physiological condition. An effective amount for a human or veterinary subject may vary depending on factors such as the condition being treated, the overall health of the subject, the method route and dose of administration and the severity of side effects. In one embodiment, an effective amount is the maximal dose or dosing protocol that avoids significant side effects or toxic effects. The effect will result in an improvement of a diagnostic measure, parameter, or detectable signal by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, where 100% is defined as the diagnostic parameter shown by a normal subject (see, e.g., Maynard, et al., *A Handbook of SOPs for Good Clinical Practice*, Interpharm Press, Boca Raton, Fla. (1996); Dent, *Good Laboratory and Good Clinical Practice*, Urch Publ., London, UK (2001)).

[0036] In another embodiment, an “effective amount” of the antagonist of IL-33 signal transduction through ST2 and IL-1RAcP means an amount sufficient to inhibit IL-33 signal transduction through ST2 and IL-1RAcP.

[0037] “Inhibiting IL-33 signal transduction through ST2 and IL-1RAcP” means that the degree to which IL-33 stimulates signal transduction through ST2 and IL-1RAcP is diminished in the presence of an antagonist, relative to the degree to which IL-33 stimulates signal transduction through ST2 and IL-1RAcP in the absence of the antagonist.

[0038] To examine the extent of inhibition, a sample is treated with a potential inhibitor and is compared to a control sample without the inhibitor. Control samples, i.e., not treated with antagonist, are assigned a relative activity value of 100%. Inhibition is achieved when the activity value relative to the control is about 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, or 20% or less.

[0039] An endpoint in inhibition may comprise a predetermined quantity or percentage of, e.g., an indicia of inflammation, oncogenicity, or cell degranulation or secretion, such as the release of a cytokine. An endpoint of inhibition is generally 75%, 50%, 25%, or 10% of the control or less.

[0040] Inhibition of IL-33 signal transduction through ST2 and IL-1RAcP can be determined by assaying for IL-33 signal transduction in an in vitro assay. One in vitro assay that

can be used is an NF- κ B-dependent reporter assay (Schmitz, J. et al., *Immunity* 23: 479-490 (2005)). In this assay, cells, e.g., HEK293FT cells, are transfected with either a mock expression vector or with an expression vector encoding ST2 in conjunction with an NF- κ B-driven reporter gene expression product, e.g., green fluorescent protein (GFP). Cells are incubated with IL-33 alone, or with IL-33 and a test molecule that is being tested for antagonistic activity. Cells are then analyzed for reporter gene expression product, e.g., by fluorescence activated cell sorting (FACS®). If IL-33 treated cells exhibit reduced reporter gene expression after incubation with the test molecule, the test molecule is an antagonist of IL-33 binding to the IL-1RAcP receptor complex.

[0041] Another reporter gene expression product that can be used is luciferase. In this assay, cellular extracts are assayed for NF- κ B-driven luciferase expression in response to incubation with IL-33, and with or without a test molecule, i.e. a putative inhibitor of IL-33 signal transduction.

[0042] Another in vitro assay that can be performed is to assay for MyD88 IRAK, IRAK4, or TRAF6 recruitment (Schmitz, J. et al., *Immunity* 23: 479-490 (2005)). In this assay, cells, e.g., HEK293FT cells, are transfected with either a mock expression vector or with an expression vector encoding ST2, and incubated with IL-33. In the control experiment, no test molecule is added to the incubation. In the test experiment, the molecule to be tested for its ability to inhibit IL-33 signal transduction is added. Cellular extracts are immunoprecipitated with an anti-ST2 antibody, followed by Western analysis with anti-MyD88, IRAK, IRAK4, or TRAF6 antibodies. A decrease in expression of MyD88, IRAK, IRAK4, or TRAF6 in extracts from IL-33 treated cells when incubated with the test molecule indicates that the test molecule is an antagonist of IL-33 binding to the IL-1RAcP receptor complex.

[0043] Another in vitro assay that can be performed is to assay for phosphorylation of Erk1/2, p38, I κ B α , or JNK (Schmitz, J. et al., *Immunity* 23: 479-490 (2005)). In this assay, cells, e.g., HEK293FT cells, are transfected with either a mock expression vector or with an expression vector encoding ST2, and incubated with IL-33. In the control experiment, no test molecule is added to the incubation. In the test experiment, the molecule to be tested for its ability to inhibit IL-33 signal transduction is added. Cellular extracts are prepared and blotted with anti-phospho-Erk1/2, anti-phospho-p38, anti-phospho-I κ B α , or anti-phospho-JNK antibodies. A decrease in the level of phosphorylated Erk1/2, p38, I κ B α , or JNK in extracts from IL-33 treated cells when incubated with the test molecule indicates that the test molecule is an antagonist of IL-33 binding to the IL-1RAcP receptor complex.

[0044] Another in vitro assay that can be performed is to assay for phosphorylation of NF- κ B, Erk1/2 or p38 in cells that naturally express ST2, e.g., mouse mast cells (WTMC) (Schmitz, J. et al., *Immunity* 23: 479-490 (2005)). In the control experiment, WTMC cells are incubated with IL-33 but no test molecule is added to the incubation. In the test experiment, cells are incubated with IL-33 and the molecule to be tested for its ability to inhibit IL-33 signal transduction. Cell lysates are separated by SDS-PAGE and electroblotted. Cellular extracts are blotted with anti-NF- κ B, anti-phospho-Erk1/2, or anti-phospho-p38 antibodies. A decrease in the level of phosphorylated NF- κ B, Erk1/2, or p38 in extracts from IL-33 treated cells when incubated with the test molecule indicates that the test molecule is an antagonist of IL-33 binding to the IL-1RAcP receptor complex.

[0045] Another in vitro assay that can be performed is to assay expression of IL-5 or IL-13 in T_H2 cells (Schmitz, J. et al., *Immunity* 23: 479-490 (2005)). In the control experiment, T_H2 cells are incubated with IL-33 but no test molecule is added to the incubation. In the test experiment, T_H2 cells are incubated with IL-33 and the molecule to be tested for its ability to inhibit IL-33 signal transduction. Supernatants are analyzed for IL-5 and IL-13 production. A decrease in the level of IL-5 or IL-13 in supernatant from IL-33 treated cells when incubated with the test molecule indicates that the test molecule is an antagonist of IL-33 binding to the IL-1RAcP receptor complex.

[0046] Another in vitro assay that can be used to determine whether a molecule is an antagonist of IL-33 binding is to determine the effect of a test molecule on IL-33-induced production of IL-6 in the mouse mast cell line WTMC. A decrease in the level of IL-6 production by IL-33 treated cells when incubated with the test molecule indicates that the test molecule is an antagonist of IL-33 binding to the IL-1RAcP receptor complex.

[0047] In vivo assays that can be used to determine whether a molecule is an antagonist of IL-33 binding to the IL-1RAcP receptor complex is to determine the effect of a test molecule on the influence of IL-33 administration on spleen size, spleen cells (e.g., mononuclear cells, eosinophils, and plasma cells), blood cell count (e.g., eosinophils, lymphocytes or neutrophils) (Schmitz, J. et al., *Immunity* 23: 479-490 (2005)). A decrease in the effect of IL-33 after administration of IL-33 and the test molecule on an in vivo endpoint, relative to the effect of IL-33 alone, indicates that the test molecule is an antagonist of IL-33 binding to the IL-1RAcP receptor complex.

[0048] In a one embodiment, the antagonist that is assayed for in the above-described assays is an antibody.

[0049] "Expression" refers to a measure of mRNA or polypeptide encoded by a specific gene. Units of expression may be a measure of, e.g., the number of molecules of mRNA or polypeptide/mg protein, the number of molecules of mRNA or polypeptide/cell, in measurements of expression by cell, tissue, cell extract, or tissue extract. The units of expression may be relative, e.g., a comparison of signal from control and experimental mammals or a comparison of signals with a reagent that is specific for the mRNA or polypeptide versus with a reagent that is non-specific.

[0050] "Immune condition" or "immune disorder" encompasses, e.g., pathological inflammation, an inflammatory disorder, and an autoimmune disorder or disease. "Immune condition" also refers to infections, persistent infections, and proliferative conditions, such as cancer, tumors, and angiogenesis.

[0051] In one embodiment, the immune disorder or immune condition is selected from the group consisting of an innate response, asthma, allergy, multiple sclerosis, inflammatory bowel disorder, arthritis, an infection, cancer, and a tumor. In another embodiment, the arthritis is selected from the group consisting of rheumatoid arthritis, osteoarthritis, and psoriatic arthritis. In another embodiment, the immune disorder or condition comprises a T_H1 -type response or a T_H2 -type response.

[0052] "Infection" refers to a disorder resulting from a pathogen, microbe, bacterium, parasite, virus, and the like. In one embodiment, the infection is caused by an organism selected from the group consisting of a bacterium, a parasite, and a virus. In another embodiment, the infection is caused by

an organism selected from the group consisting of *Leishmania* sp., *Mycobacterium* sp., *Listeria* sp., *Toxoplasma* sp., *Schistosoma* sp., and a respiratory virus.

[0053] "Inflammatory disorder" means a disorder or pathological condition where the pathology results, in whole or in part, from, e.g., a change in number, change in rate of migration, or change in activation, of cells of the immune system. Cells of the immune system include, e.g., T cells, B cells, monocytes or macrophages, antigen presenting cells (APCs), dendritic cells, microglia, NK cells, NKT cells, neutrophils, eosinophils, mast cells, or any other cell specifically associated with the immunology, for example, cytokine-producing endothelial or epithelial cells.

[0054] "IL-1RAcP" means the Interleukin-1 Receptor Accessory Protein. IL-1RAcP is further described at online Mendelian Inheritance in Man (OMIM) entry 602626 and Gene ID No. 3556, and exemplary naturally occurring sequences for human IL-1RAcP are found at GenBank Accession Nos. NP_608273 and NP_002173, all of which are available through the National Center for Biotechnology Information (NCBI) website.

[0055] "IL-33 receptor complex" refers to the specific binding of ST2 to IL-1RAcP to form a protein complex that itself specifically binds to IL-33 and transduces the IL-33 signal from the cell surface to the cell interior.

[0056] "IL-33/ST2 complex" refers to the specific binding of IL-33 and ST2 to form a protein complex that itself specifically binds to IL-1RAcP. IL-33 is further described at OMIM entry 608678 and Gene ID No. 90865, and an exemplary naturally occurring sequence for human IL-33 is found at GenBank Accession No. AY905581, all of which are available through the NCBI website. See also Schmitz et al. (2005) *Immunity* 23: 479-490.

[0057] An "isolated and purified" complex, such as an isolated and purified complex of ST2 and IL-1RAcP, optionally further comprising IL-33, is an in vitro complex that is isolated and purified from its natural source. Specifically, an isolated and purified complex does not encompass complexes as they form in nature. Such complexes may be formed, e.g., by mixture of two or more purified proteins, or by mixture of one purified protein with a cell extract or biological sample, or by the purification of a complex from a natural source.

[0058] "IL-33 signal transduction through ST2 and IL-1RAcP" refers to the molecular events that occur when IL-33, ST2 and IL-1RAcP form a protein complex. In one embodiment, the IL-33 signal transduction refers to recruitment of one or more of MyD88, IRAK, IRAK4, and TRAF6 to ST2 in response to the formation of a complex of IL-33, ST2, and IL-1RAcP. In another embodiment, IL-33 signal transduction refers to phosphorylation of one or more of I κ B κ , Erk1/2, p38 and JNK in response to the formation of a complex of IL-33, ST2, and IL-1RAcP. In another embodiment, IL-33 signal transduction refers to IL-5 or IL-13 secretion by T_H2 cells.

[0059] Specificity of binding refers to a binding interaction between a predetermined ligand and a predetermined receptor that enables one to distinguish between the predetermined ligand and other ligands, or between the predetermined receptor and other receptors. In one embodiment, the ligand is IL-33, and the receptor is ST2. In another embodiment, the ligand is IL-33, and the receptor is a protein complex of ST2 and IL-1RAcP. In another embodiment, the ligand is a protein complex of IL-33 and ST2, and the receptor is IL-1RAcP. In another embodiment, the ligand is an antibody or a fragment

thereof that specifically binds to IL-33, IL-1RAcP, ST2, a complex of ST2 bound to IL-1RAcP, a complex of IL-33 bound to ST2, or a complex of IL-33, ST2 and IL-1RAcP.

[0060] A “pharmaceutical composition” comprises the active drug ingredient and one or more pharmaceutically acceptable excipients, carriers and/or diluents.

[0061] “Specifically binds” means a binding reaction that is determinative of the presence of a protein in a heterogeneous population of proteins and other biologics. For example, under designated conditions, one protein binds to another protein and does not bind in a significant amount to other proteins present in the sample. In various embodiments, an antibody or fragment thereof binds to its antigen with an affinity that is at least two fold greater, at least ten times greater, at least 20-times greater, or at least 100-times greater than the affinity to any other protein.

[0062] In various embodiments, an antibody, or fragment thereof, that specifically binds to IL-33, IL-1RAcP, ST2, a complex of ST2 bound to IL-1RAcP, a complex of IL-33 bound to ST2, or a complex of IL-33, ST2 and IL-1RAcP will bind with a K_D of at least about 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M, 10^{-10} M, or 10^{-11} M or better (lower K_D).

[0063] “ST2” as used herein is synonymous with the T1/ST2 protein (also known as IL-1RL1). ST2 is further described at OMIM entry 601203 and Gene ID No. 9173, and exemplary naturally occurring sequences for human ST2 are found at GenBank Accession Nos. NP_003847 and NP_057316, all of which are available through the NCBI website.

[0064] “ST2/IL-1RAcP complex” refers to the specific binding of ST2 and IL-1RAcP to form a protein complex that itself specifically binds IL-33.

[0065] Purification of antigen is not necessary for the generation of antibodies. Immunization can be performed by DNA vector immunization, see, e.g., Wang, et al. *Virology* 228:278-284 (1997). Alternatively, animals can be immunized with cells bearing the antigen of interest. Splenocytes can then be isolated from the immunized animals, and the splenocytes can be fused with a myeloma cell line to produce a hybridoma (Meygaard et al., *Immunity* 7:283-290 (1997); Wright et al., *Immunity* 13:233-242 (2000); Preston et al., *Eur. J. Immunol.* 27:1911-1918 (1997)). Resultant hybridomas can be screened for production of the desired antibody by functional assays or biological assays, that is, assays not dependent on possession of the purified antigen. Immunization with cells may prove superior for antibody generation than immunization with purified antigen (Kaithamana et al., *J. Immunol.* 163:5157-5164 (1999)).

[0066] Any suitable method can be used to elicit an antagonist antibody with the desired biologic properties. It may be desirable to prepare monoclonal antibodies (mAbs) from mammalian hosts such as mice, rodents, primates, humans, etc. Techniques for preparing such monoclonal antibodies may be found in, e.g., Stites et al. (eds.) *BASIC AND CLINICAL IMMUNOLOGY* (4th ed.) Lange Medical Publications, Los Altos, Calif., and references cited therein; Harlow and Lane (1988) *ANTIBODIES: A LABORATORY MANUAL* CSH Press; Goding (1986) *MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE* (2d ed.) Academic Press, New York, N.Y. Thus, monoclonal antibodies may be obtained by a variety of techniques familiar to researchers skilled in the art. Typically, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell. See Kohler and Milstein (1976) *Eur. J. Immunol.* 6:511-519.

Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods known in the art. See, e.g., Doyle et al. (eds. 1994 and periodic supplements) *CELL AND TISSUE CULTURE: LABORATORY PROCEDURES*, John Wiley and Sons, New York, N.Y. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a monoclonal antibody or a antigen binding fragment thereof by screening a DNA library from human B cells according, e.g., to the general protocol outlined by Huse et al. (1989) *Science* 246:1275-1281.

[0067] Other suitable techniques involve selection of libraries of antibodies in phage or similar vectors. See, e.g., Huse et al. supra; and Ward et al. (1989) *Nature* 341:544-546. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabilly U.S. Pat. No. 4,816,567; and Queen et al. (1989) *Proc. Nat'l Acad. Sci. USA* 86:10029-10033; or made in transgenic mice, see Mendez et al. (1997) *Nature Genetics* 15:146-156. See also Abgenix and Medarex technologies.

[0068] Any suitable non-human antibody can be used as a source for the hypervariable region of a humanized antibody. Sources for non-human antibodies include, but are not limited to, murine, Lagomorphs (including rabbits), bovine, and primates. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance of the desired biological activity. For further details, see Jones et al. (1986) *Nature* 321:522-525; Reichmann et al. (1988) *Nature* 332:323-329; and Presta (1992) *Curr. Op. Struct. Biol.* 2:593-596.

[0069] Methods for recombinantly engineering antibodies have been described, e.g., by Boss et al. (U.S. Pat. No. 4,816,397), Cabilly et al. (U.S. Pat. No. 4,816,567), Law et al. (European Patent Application Publication No. 438310) and Winter (European Patent Application Publication No. 239400).

[0070] In one embodiment, the antagonist of the present invention is administered in a pharmaceutical composition. In

another embodiment, the antagonist of the present invention is administered in a sterile composition.

[0071] To prepare pharmaceutical or sterile compositions, an active drug ingredient is mixed with one or more pharmaceutically acceptable carriers, excipients and/or diluents. A Pharmaceutical formulation can be prepared in the form of, e.g., a lyophilized powder, an aqueous solution, or a suspension. See, e.g., Hardman, et al., *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, McGraw-Hill, New York, N.Y. (2001); Gennaro, *Remington: The Science and Practice of Pharmacy*, Lippincott, Williams, and Wilkins, New York, N.Y. (2000); Avis, et al. (eds.), *Pharmaceutical Dosage Forms: Parenteral Medications*, Marcel Dekker, NY (1993); *Excipient Toxicity and Safety*, Marcel Dekker, Inc., New York, N.Y. (2000).

[0072] Selecting an administration regimen for a therapeutic depends on several factors, including the serum or tissue turnover rate of the entity, the level of symptoms, the immunogenicity of the entity, and the accessibility of the target cells in the biological matrix. Preferably, an administration regimen maximizes the amount of therapeutic delivered to the patient consistent with an acceptable level of side effects. Accordingly, the amount of biologic delivered depends in part on the particular entity and the severity of the condition being treated. Guidance in selecting appropriate doses of antibodies is available. See, e.g., Wawrzynczak, *Antibody Therapy*, Bios Scientific Pub. Ltd, Oxfordshire, UK (1996); Kresina (ed.), *Monoclonal Antibodies, Cytokines and Arthritis*, Marcel Dekker, New York, N.Y. (1991); Bach (ed.), *Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases*, Marcel Dekker, New York, N.Y. (1993).

[0073] An antibody or fragment thereof can be provided by continuous infusion, or by doses at intervals. An antibody or fragment thereof may be administered intravenously, intramuscularly, or subcutaneously.

[0074] A preferred dose protocol is one involving the maximal dose or dose frequency that avoids significant undesirable side effects. In various embodiments, the total weekly dose is 0.05 µg/kg, 0.2 µg/kg, 0.5 µg/kg, 1 µg/kg, 10 µg/kg, 100 µg/kg, 0.2 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 10 mg/kg, 25 mg/kg, 50 mg/kg or more.

[0075] An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the method route and dose of administration and the severity of side affects (see, e.g., Maynard, et al., *A Handbook of SOPs for Good Clinical Practice*, Interpharm Press, Boca Raton, Fla. (1996); Dent, *Good Laboratory and Good Clinical Practice*, Urch Publ., London, UK (2001)).

[0076] Determination of the appropriate dose is made by the clinician, e.g., using parameters or factors known or suspected in the art to affect treatment or predicted to affect treatment. Generally, the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved relative to any negative side effects. Important diagnostic measures include those of symptoms of, e.g., the inflammation or level of inflammatory cytokines produced. Preferably, a biologic that will be used is derived from the same species as the animal targeted for treatment, thereby minimizing a humoral response to the reagent.

[0077] The present invention also provides a method of modulating blood cell counts, the method comprising administering an effective amount of an antagonist of IL-33 signal

transduction through ST2 and IL-1RAcP. In one embodiment, the antagonist increases the count of platelets. In another embodiment, the antagonist decreases the counts of total white blood cells, neutrophils, lymphocytes, and/or eosinophils.

[0078] The present invention also provides methods and kits for the diagnosis of an immune condition or disorder. A method of diagnosis can comprise contacting a sample from a subject, e.g., a test subject, with an antibody or fragment thereof that specifically binds to (a) IL-33, (b) IL-1RAcP, (c) ST2, (d) a complex of ST2 and IL-1RAcP, (e) a complex of IL-33 and ST2, or (f) a complex of IL-33, ST2 and IL-1RAcP. The method can further comprise contacting a sample from a control subject, normal subject, or normal tissue or fluid from the test subject, with an antibody or fragment thereof. Moreover, the method can additionally comprise comparing the specific binding of the antibody or fragment thereof to the test subject with the specific binding of the composition to the normal subject, control subject, or normal tissue or fluid from the test subject. Expression or activity of a test sample or test subject can be compared with that from a control sample or control subject. A control sample can comprise, e.g., a sample of non-affected or non-inflamed tissue in a patient suffering from an immune disorder. Expression or activity from a control subject or control sample can be provided as a predetermined value, e.g., acquired from a statistically appropriate group of control subjects.

[0079] Kits for the diagnosis of an immune condition or disorder may comprise a compartment and a binding compound, e.g. an antibody or antigen-binding fragment thereof, that specifically binds to one or more components of IL-33 signal transduction through ST2 and IL-1RAcP. Such kits may optionally include instructions for use. In some embodiments the binding compound is detectably labeled.

[0080] The broad scope of this invention is best understood with reference to the following examples, which are not intended to limit the inventions to specific embodiments.

[0081] Many modifications and variations of this invention, as will be apparent to one of ordinary skill in the art can be made to adapt to a particular situation, material, composition of matter, process, process step or steps, to preserve the objective, spirit and scope of the invention. All such modifications are intended to be within the scope of the claims appended hereto without departing from the spirit and scope of the invention. The specific embodiments described herein are offered by way of example only, and the invention includes the full scope of equivalents to which such claims are entitled; and the invention is not to be limited by the specific embodiments that have been presented herein.

[0082] All citations herein are incorporated herein by reference to the same extent as if each individual publication, patent application, patent, database entry or other document was specifically and individually indicated to be incorporated by reference including all figures and drawings.

Example 1

Animal Experiments

[0083] In order to determine whether IL-1RAcP is the second member of the receptor complex, wild-type (WT) and IL-1RAcP deficient (KO) mice were used. The wild-type (WT) mice used were strain B6;129SF2/J (Jackson Laboratories). The IL-1RAcP deficient (KO) mice used were strain B6;129S1-Il1rap^{tm1/Rom1}/J (Jackson Laboratories). The

IL-1RAcP deficient mice have been genetically altered and do not have a functional IL-1RAcP receptor protein.

[0084] Wild-type and IL-1RAcP deficient mice were given daily intraperitoneal injections of saline or 2 micrograms of human IL-33 for six days. On day seven, the mice were sacrificed and analyzed for IL-33 responsiveness by several endpoints, as discussed in the following Examples. Blood eosinophilia was measured in blood smears. Serum and bronchoalveolar lavage (BAL) fluid were collected to quantitate cytokine levels and serum immunoglobulin (Ig) E levels. Lung and spleen tissue was collected to quantitate messenger RNA of key cytokines. Lung and small intestine tissue was analyzed for histological changes. Two replicate experiments were performed with either three or five mice per treatment group.

[0085] The following data show that IL-1RAcP deficient mice do not respond to IL-33 administration, indicating that IL-1RAcP is necessary to mediate the *in vivo* effects of IL-33. These results implicate IL-1RAcP as the second component of the IL-33 receptor.

Example 2

Lack of Blood Eosinophilia in IL-1RAcP Deficient Mice

[0086] Tail blood was smeared onto glass slides, fixed in 95% ethanol, and stained by the Wright-Giemsa method. Cells were enumerated by microscope, and at least 300 cells were counted per mouse. The graphs in FIGS. 1A and 1B represent the two replicate experiments performed, involving five and three animals, respectively. IL-33 administration to wild-type mice dramatically increased the percentage of eosinophils found in the blood. However the percent of eosinophils in the blood of IL-33-treated IL-1RAcP deficient mice was not increased, and was similar to saline treated mice.

Example 3

Lack of Goblet Cell Hyperplasia and Mucous Production in IL-1RAcP Deficient Mice

[0087] Formalin-fixed, paraffin-embedded small intestines were stained by Periodic acid-Schiff. Wild-type mice, but not IL-1RAcP deficient mice, responded to IL-33 with increased goblet cell mucous production in the small intestine. A total of eight mice were examined per treatment condition. A similar finding was noted in the upper airways of the lung.

Example 4

IL-1RAcP Deficient Mice Fail to Respond to IL-33 with Increased Production of IL-5

[0088] Serum and BAL fluid were analyzed for cytokine content by multiplex immunoassay. In both the serum (FIG. 2A) and BAL fluid (FIG. 2B), IL-33 treatment dramatically increased the production of IL-5 in wild-type mice, but not in IL-1RAcP deficient mice. The data are representative of two experiments.

Example 5

Serum Levels of IgE are Increased in Wild-Type but not IL-1RAcP Deficient Mice

[0089] Serum IgE levels were measured by ELISA. IL-33 increased serum IgE in wild-type, but not in IL-1RAcP deficient mice (FIG. 3). The data are representative of two experiments.

Example 6

IL-1RAcP Deficient Mice do not Upregulate T_H2 Cytokine Genes In Response to IL-33 Administration

[0090] RT-PCR was performed on RNA obtained from snap-frozen spleen and lung tissue, and gene expression is shown in FIG. 4, relative to the levels of ubiquitin (ub) in the sample. IL-33 increased mRNA expression of the T helper 2 (T_H2) cytokines and cytokine receptors IL-4 (FIG. 4A), IL-5 (FIG. 4C), IL-6 (FIG. 4B), IL-13 (FIG. 4D), IL-17RB (FIG. 4E), and ST2 (FIG. 4F), in the lung and spleen of wild-type mice, but not in IL-1RAcP deficient ("KO") mice.

Example 7

IL-33 Induces IL-6 Production in WTMC Cells

[0092] The mouse mast cell line WTMC (Wright, G. J., et al., *J. Immunol.* 171: 3034-3046 (2003)), expresses ST2 and responds to both human and mouse IL-33 in a dose dependent manner by producing IL-6. IL-33 activity can be blocked by preincubating the cells with a blocking rat anti-mouse ST2 antibody (MD Biosciences).

[0093] 1×10^5 WTMCs were plated per well (96-well plate format) in RPMI 1640 w/ L-glutamine containing 10% fetal calf serum, 1 mM Na-Pyruvate, 0.05 mM 2-mercapto-ethanol, 0.2 mM L-glutamine, 1xMEM non-essential amino acids, 1x PenStrep, 2.5 ng/ml mouse IL-3, and 2.5 ng/ml mouse IL-4. Cells were incubated for 24 hours with varying concentrations of mouse or human IL-33. Supernatants were assessed for IL-6 production by ELISA. As shown in FIG. 5, IL-33 induced IL-6 production in a dose dependent manner.

[0094] As shown in FIG. 6, a blocking rat anti-mouse ST2 antibody (MD Biosciences) prevented IL-33 induced production in WTMCs. Mast cells were seeded with into 24 well plates at 1×10^6 cells/well. Some cells were preincubated with anti-ST2 antibody (10 μ g/ml) prior to the addition of IL-33 (50 ng/ml). Supernatants were collected after 6 and 24 hours and analyzed for cytokine production by multiplex immunoassay.

Example 8

IL-1RAcP is Necessary for IL-33-Enhanced IL-5, IL-6, and IL-13 Production From T_H2 Cells

[0095] CD4⁺ T cells were isolated from wildtype (B6; 129SF2/J) and IL-1RAcP knock-out (B6;129S1-Il1rap^{tm1/Rom1}/J) mouse spleen and lymph nodes using the CD4⁺ T cell isolation kit (Miltenyi Biotec). To polarize towards a T_H2 phenotype, cells were cultured on anti-CD3 coated plates in the presence of 5 ng/ml IL-2, 10 ng/ml IL-4, 10 μ g/ml anti-IFN γ , and 1 μ g/ml anti-CD28 in complete RPMI for 4 days. Cells were then washed, and rested for 3 days in IL-2 (5 ng/ml) alone. Cells were then washed and stimulated with media alone, human IL-33 (50 ng/ml), or mouse IL-1 β (10 ng/ml). Some cells were preincubated with anti-ST2 blocking antibody prior to cytokine addition. Supernatants were harvested after 24 hours and cytokine levels were measured using a multiplexed immunoassay (22-plex mouse cytokine premixed beads, Linco), and analyzed by Luminex[®] immunoassay.

[0096] As shown in FIG. 7, both IL-1 β and IL-33 enhanced the production of IL-13, IL-6, and IL-5 in wildtype, but not IL-1RAcP^{-/-} T_H2 cells. The increased production of these cytokines in wildtype mice by IL-33 was blocked in the

presence of anti-ST2 antibodies. Anti-ST2 did not block IL-1 β -enhanced cytokine production.

Example 9

Detection of the ST2/IL-33/IL-1RAcP Complex

[0097] Murine IL-113 or IL-33 was titrated into plates containing soluble his6-tagged murine IL-1RAcP and plate-bound ST2-Fc (FIG. 8A) or IL-1R1—Fc (FIG. 8B). Peroxidase-conjugated anti-his6 was used as a detection antibody. Data is representative of 2 experiments. Data represent the mean $\pm$ SEM of duplicate wells.

[0098] Receptor-ligand complex ELISA: 3 μ g/ml murine ST2-Fc or IL-1R1—Fc fusion proteins (R&D Systems) in PBS were coated overnight onto MaxiSorp plates (Nunc). After washing, plates were incubated with 3 μ g/ml recombinant his6-tagged murine IL-1RAcP and increasing concentrations of murine IL-33 or IL-113 in PBS/1% bovine serum albumin/0.05% Tween-20® polyoxyethylene sorbitan monolaurate for 1.5 hours. Plates were washed and incubated with anti-his6-peroxidase (Roche Diagnostics) for 1 hour, washed again, developed with TMB Peroxidase substrate (KPL), stopped with H₂PO₄, and read on a plate reader at 450-570 nm.

[0099] Although IL-1RAcP is required to mediate the effects of IL-33 in vivo and on Th2 cells, the possibility exists that this is due to an indirect rather than a direct interaction of IL-33 and IL-1RAcP. Therefore, we wished to detect formation of the ligand-receptor complex in vitro. In the IL-1 receptor complex, IL-1RAcP cannot bind IL-1 directly, rather it is hypothesized to interact with the complex of IL-1 and its primary receptor, IL-1R1. We are also unable to see a direct interaction of IL-33 with IL-1RAcP (not shown). However, we can detect a specific ST2/IL-33/IL-1RAcP complex by ELISA. We titrated IL-33 or IL-113 into wells containing plate-bound ST2 and soluble his6-tagged IL-1RAcP (FIG. 8A). We detect IL-33 receptor complex formation with an anti-his6 antibody as the concentration of IL-33, but not IL-1 β , increases. Conversely, if the plates are coated with IL-1R1 instead of ST2, we detect IL-1 receptor complex formation with increasing amounts of IL-1 β but not IL-33 (FIG. 8B). This result demonstrates that ST2, IL-33, and IL-1RAcP can form a ligand/receptor complex.

Example 10

Dominant Negative IL-1RAcP Inhibits IL-33 Signaling

[0100] Signal transduction by IL-1RAcP in the IL-1 signaling cascade is mediated by its cytoplasmic Toll/IL-1 receptor (TIR) domain and involves recruitment of the adaptor MyD88 and activation of NF- κ B. IL-33 uses the same signaling components as IL-1, including IRAK, IRAK4, MyD88, and TRAF6, leading to the activation of NF- κ B and MAP kinases. MyD88 is required for IL-33 signaling, as MyD88 $^{-/-}$ mice do not respond to IL-33 administration (data not shown). In order to investigate the contribution of IL-1RAcP to IL-33 signal transduction, we used a dominant negative form of IL-1RAcP that contains a stop codon before the TIR domain.

[0101] As a positive control, HEK293FT cells, which endogenously express human IL-1R1 and IL-1RAcP, were transfected with 3 μ g of a NF- κ B-driven reporter gene construct (pNF- κ B-hrGFP, Stratagene), and with increasing amounts of cMyc-tagged murine dominant negative (dn) IL-1RAcP construct. Cells were stimulated at 24 hours post-transfection with 20 ng/ml murine IL-1 α (R&D Systems) for 24 hours, and analyzed for GFP expression by FACS® cell sorting. This control tests the ability of the dn IL-1RAcP to interact with the endogenous IL-1R1 and block IL-1 α mediated downstream signaling. This interaction is reflected by the diminution of GFP expression when increasing amounts of the dn IL-1RAcP are transfected into control cells (FIG. 9, bottom row).

[0102] For experimental samples, HEK293FT cells were transfected with 1 μ g of a plasmid encoding murine ST2, 3 μ g of the NF- κ B-driven reporter gene construct, and with increasing amounts of cMyc-tagged murine dominant negative (dn) IL-1RAcP construct. Cells were stimulated at 24 hours post-transfection with 20 ng/ml murine IL-33 for 24 hours, and analyzed for GFP expression by FACS® cell sorting. Results of a typical experiment are provided at FIG. 9 (top row). This experimental system tests the ability of the dn IL-1RAcP to interact with murine ST2 and block IL-33 signaling. The addition of the dn IL-1RAcP caused a roughly dose-responsive decrease in IL-33-induced reporter gene expression, suggesting that ST2 uses IL-1RAcP as a second receptor to mediate IL-33 signal transduction.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 5

<210> SEQ ID NO 1

<211> LENGTH: 356

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```
Met Thr Leu Leu Trp Cys Val Val Ser Leu Tyr Phe Tyr Gly Ile Leu
1          5          10          15

Gln Ser Asp Ala Ser Glu Arg Cys Asp Asp Trp Gly Leu Asp Thr Met
          20          25          30

Arg Gln Ile Gln Val Phe Glu Asp Glu Pro Ala Arg Ile Lys Cys Pro
          35          40          45
```

-continued

Leu Phe Glu His Phe Leu Lys Phe Asn Tyr Ser Thr Ala His Ser Ala
 50 55 60
 Gly Leu Thr Leu Ile Trp Tyr Trp Thr Arg Gln Asp Arg Asp Leu Glu
 65 70 75 80
 Glu Pro Ile Asn Phe Arg Leu Pro Glu Asn Arg Ile Ser Lys Glu Lys
 85 90 95
 Asp Val Leu Trp Phe Arg Pro Thr Leu Leu Asn Asp Thr Gly Asn Tyr
 100 105 110
 Thr Cys Met Leu Arg Asn Thr Thr Tyr Cys Ser Lys Val Ala Phe Pro
 115 120 125
 Leu Glu Val Val Gln Lys Asp Ser Cys Phe Asn Ser Pro Met Lys Leu
 130 135 140
 Pro Val His Lys Leu Tyr Ile Glu Tyr Gly Ile Gln Arg Ile Thr Cys
 145 150 155 160
 Pro Asn Val Asp Gly Tyr Phe Pro Ser Ser Val Lys Pro Thr Ile Thr
 165 170 175
 Trp Tyr Met Gly Cys Tyr Lys Ile Gln Asn Phe Asn Asn Val Ile Pro
 180 185 190
 Glu Gly Met Asn Leu Ser Phe Leu Ile Ala Leu Ile Ser Asn Asn Gly
 195 200 205
 Asn Tyr Thr Cys Val Val Thr Tyr Pro Glu Asn Gly Arg Thr Phe His
 210 215 220
 Leu Thr Arg Thr Leu Thr Val Lys Val Val Gly Ser Pro Lys Asn Ala
 225 230 235 240
 Val Pro Pro Val Ile His Ser Pro Asn Asp His Val Val Tyr Glu Lys
 245 250 255
 Glu Pro Gly Glu Glu Leu Leu Ile Pro Cys Thr Val Tyr Phe Ser Phe
 260 265 270
 Leu Met Asp Ser Arg Asn Glu Val Trp Trp Thr Ile Asp Gly Lys Lys
 275 280 285
 Pro Asp Asp Ile Thr Ile Asp Val Thr Ile Asn Glu Ser Ile Ser His
 290 295 300
 Ser Arg Thr Glu Asp Glu Thr Arg Thr Gln Ile Leu Ser Ile Lys Lys
 305 310 315 320
 Val Thr Ser Glu Asp Leu Lys Arg Ser Tyr Val Cys His Ala Arg Ser
 325 330 335
 Ala Lys Gly Glu Val Ala Lys Ala Ala Lys Val Lys Gln Lys Gly Asn
 340 345 350
 Arg Cys Gly Gln
 355

<210> SEQ ID NO 2

<211> LENGTH: 570

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

Met Thr Leu Leu Trp Cys Val Val Ser Leu Tyr Phe Tyr Gly Ile Leu
 1 5 10 15
 Gln Ser Asp Ala Ser Glu Arg Cys Asp Asp Trp Gly Leu Asp Thr Met
 20 25 30
 Arg Gln Ile Gln Val Phe Glu Asp Glu Pro Ala Arg Ile Lys Cys Pro
 35 40 45

-continued

Leu	Phe	Glu	His	Phe	Leu	Lys	Phe	Asn	Tyr	Ser	Thr	Ala	His	Ser	Ala
50						55					60				
Gly	Leu	Thr	Leu	Ile	Trp	Tyr	Trp	Thr	Arg	Gln	Asp	Arg	Asp	Leu	Glu
65					70					75				80	
Glu	Pro	Ile	Asn	Phe	Arg	Leu	Pro	Glu	Asn	Arg	Ile	Ser	Lys	Glu	Lys
				85					90					95	
Asp	Val	Leu	Trp	Phe	Arg	Pro	Thr	Leu	Leu	Asn	Asp	Thr	Gly	Asn	Tyr
			100					105					110		
Thr	Cys	Met	Leu	Arg	Asn	Thr	Thr	Tyr	Cys	Ser	Lys	Val	Ala	Phe	Pro
	115					120						125			
Leu	Glu	Val	Val	Gln	Lys	Asp	Ser	Cys	Phe	Asn	Ser	Pro	Met	Lys	Leu
130						135						140			
Pro	Val	His	Lys	Leu	Tyr	Ile	Glu	Tyr	Gly	Ile	Gln	Arg	Ile	Thr	Cys
145					150					155					160
Pro	Asn	Val	Asp	Gly	Tyr	Phe	Pro	Ser	Ser	Val	Lys	Pro	Thr	Ile	Thr
				165					170					175	
Trp	Tyr	Met	Gly	Cys	Tyr	Lys	Ile	Gln	Asn	Phe	Asn	Asn	Val	Ile	Pro
		180						185					190		
Glu	Gly	Met	Asn	Leu	Ser	Phe	Leu	Ile	Ala	Leu	Ile	Ser	Asn	Asn	Gly
		195					200					205			
Asn	Tyr	Thr	Cys	Val	Val	Thr	Tyr	Pro	Glu	Asn	Gly	Arg	Thr	Phe	His
	210					215					220				
Leu	Thr	Arg	Thr	Leu	Thr	Val	Lys	Val	Val	Gly	Ser	Pro	Lys	Asn	Ala
225					230					235					240
Val	Pro	Pro	Val	Ile	His	Ser	Pro	Asn	Asp	His	Val	Val	Tyr	Glu	Lys
				245					250					255	
Glu	Pro	Gly	Glu	Glu	Leu	Leu	Ile	Pro	Cys	Thr	Val	Tyr	Phe	Ser	Phe
			260					265					270		
Leu	Met	Asp	Ser	Arg	Asn	Glu	Val	Trp	Trp	Thr	Ile	Asp	Gly	Lys	Lys
		275					280					285			
Pro	Asp	Asp	Ile	Thr	Ile	Asp	Val	Thr	Ile	Asn	Glu	Ser	Ile	Ser	His
	290					295					300				
Ser	Arg	Thr	Glu	Asp	Glu	Thr	Arg	Thr	Gln	Ile	Leu	Ser	Ile	Lys	Lys
305					310					315					320
Val	Thr	Ser	Glu	Asp	Leu	Lys	Arg	Ser	Tyr	Val	Cys	His	Ala	Arg	Ser
			325						330					335	
Ala	Lys	Gly	Glu	Val	Ala	Lys	Ala	Ala	Lys	Val	Lys	Gln	Lys	Val	Pro
			340				345						350		
Ala	Pro	Arg	Tyr	Thr	Val	Glu	Leu	Ala	Cys	Gly	Phe	Gly	Ala	Thr	Val
	355						360					365			
Leu	Leu	Val	Val	Ile	Leu	Ile	Val	Val	Tyr	His	Val	Tyr	Trp	Leu	Glu
370					375						380				
Met	Val	Leu	Phe	Tyr	Arg	Ala	His	Phe	Gly	Thr	Asp	Glu	Thr	Ile	Leu
385					390					395					400
Asp	Gly	Lys	Glu	Tyr	Asp	Ile	Tyr	Val	Ser	Tyr	Ala	Arg	Asn	Ala	Glu
			405					410						415	
Glu	Glu	Glu	Phe	Val	Leu	Leu	Thr	Leu	Arg	Gly	Val	Leu	Glu	Asn	Glu
			420					425					430		
Phe	Gly	Tyr	Lys	Leu	Cys	Ile	Phe	Asp	Arg	Asp	Ser	Leu	Pro	Gly	Gly
		435					440					445			

-continued

```

Ile Val Thr Asp Glu Thr Leu Ser Phe Ile Gln Lys Ser Arg Arg Leu
 450                      455                      460

Leu Val Val Leu Ser Pro Asn Tyr Val Leu Gln Gly Thr Gln Ala Leu
465                      470                      475                      480

Leu Glu Leu Lys Ala Gly Leu Glu Asn Met Ala Ser Arg Gly Asn Ile
                      485                      490                      495

Asn Val Ile Leu Val Gln Tyr Lys Ala Val Lys Glu Thr Lys Val Lys
                    500                      505                      510

Glu Leu Lys Arg Ala Lys Thr Val Leu Thr Val Ile Lys Trp Lys Gly
                    515                      520                      525

Glu Lys Ser Lys Tyr Pro Gln Gly Arg Phe Trp Lys Gln Leu Gln Val
                    530                      535                      540

Ala Met Pro Val Lys Lys Ser Pro Arg Arg Ser Ser Ser Asp Glu Gln
545                      550                      555                      560

Gly Leu Ser Tyr Ser Ser Leu Lys Asn Val
                    565                      570

```

```

<210> SEQ ID NO 3
<211> LENGTH: 270
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

```

```

Met Lys Pro Lys Met Lys Tyr Ser Thr Asn Lys Ile Ser Thr Ala Lys
 1                      5                      10                      15

Trp Lys Asn Thr Ala Ser Lys Ala Leu Cys Phe Lys Leu Gly Lys Ser
                      20                      25                      30

Gln Gln Lys Ala Lys Glu Val Cys Pro Met Tyr Phe Met Lys Leu Arg
                      35                      40                      45

Ser Gly Leu Met Ile Lys Lys Glu Ala Cys Tyr Phe Arg Arg Glu Thr
50                      55                      60

Thr Lys Arg Pro Ser Leu Lys Thr Gly Arg Lys His Lys Arg His Leu
65                      70                      75                      80

Val Leu Ala Ala Cys Gln Gln Gln Ser Thr Val Glu Cys Phe Ala Phe
                      85                      90                      95

Gly Ile Ser Gly Val Gln Lys Tyr Thr Arg Ala Leu His Asp Ser Ser
100                      105                      110

Ile Thr Gly Ile Ser Pro Ile Thr Glu Tyr Leu Ala Ser Leu Ser Thr
115                      120                      125

Tyr Asn Asp Gln Ser Ile Thr Phe Ala Leu Glu Asp Glu Ser Tyr Glu
130                      135                      140

Ile Tyr Val Glu Asp Leu Lys Lys Asp Glu Lys Lys Asp Lys Val Leu
145                      150                      155                      160

Leu Ser Tyr Tyr Glu Ser Gln His Pro Ser Asn Glu Ser Gly Asp Gly
165                      170                      175

Val Asp Gly Lys Met Leu Met Val Thr Leu Ser Pro Thr Lys Asp Phe
180                      185                      190

Trp Leu His Ala Asn Asn Lys Glu His Ser Val Glu Leu His Lys Cys
195                      200                      205

Glu Lys Pro Leu Pro Asp Gln Ala Phe Phe Val Leu His Asn Met His
210                      215                      220

Ser Asn Cys Val Ser Phe Glu Cys Lys Thr Asp Pro Gly Val Phe Ile
225                      230                      235                      240

```

-continued

Gly Val Lys Asp Asn His Leu Ala Leu Ile Lys Val Asp Ser Ser Glu
 245 250 255

Asn Leu Cys Thr Glu Asn Ile Leu Phe Lys Leu Ser Glu Thr
 260 265 270

<210> SEQ ID NO 4
 <211> LENGTH: 328
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: SIGNAL
 <222> LOCATION: (1) .. (18)
 <220> FEATURE:
 <221> NAME/KEY: CHAIN
 <222> LOCATION: (19) .. (328)

<400> SEQUENCE: 4

Met Gly Phe Trp Ile Leu Ala Ile Leu Thr Ile Leu Met Tyr Ser Thr
 1 5 10 15

Ala Ala Lys Phe Ser Lys Gln Ser Trp Gly Leu Glu Asn Glu Ala Leu
 20 25 30

Ile Val Arg Cys Pro Arg Gln Gly Lys Pro Ser Tyr Thr Val Asp Trp
 35 40 45

Tyr Tyr Ser Gln Thr Asn Lys Ser Ile Pro Thr Gln Glu Arg Asn Arg
 50 55 60

Val Phe Ala Ser Gly Gln Leu Leu Lys Phe Leu Pro Ala Ala Val Ala
 65 70 75 80

Asp Ser Gly Ile Tyr Thr Cys Ile Val Arg Ser Pro Thr Phe Asn Arg
 85 90 95

Thr Gly Tyr Ala Asn Val Thr Ile Tyr Lys Lys Gln Ser Asp Cys Asn
 100 105 110

Val Pro Asp Tyr Leu Met Tyr Ser Thr Val Ser Gly Ser Glu Lys Asn
 115 120 125

Ser Lys Ile Tyr Cys Pro Thr Ile Asp Leu Tyr Asn Trp Thr Ala Pro
 130 135 140

Leu Glu Trp Phe Lys Asn Cys Gln Ala Leu Gln Gly Ser Arg Tyr Arg
 145 150 155 160

Ala His Lys Ser Phe Leu Val Ile Asp Asn Val Met Thr Glu Asp Ala
 165 170 175

Gly Asp Tyr Thr Cys Lys Phe Ile His Asn Glu Asn Gly Ala Asn Tyr
 180 185 190

Ser Val Thr Ala Thr Arg Ser Phe Thr Val Lys Asp Glu Gln Gly Phe
 195 200 205

Ser Leu Phe Pro Val Ile Gly Ala Pro Ala Gln Asn Glu Ile Lys Glu
 210 215 220

Val Glu Ile Gly Lys Asn Ala Asn Leu Thr Cys Ser Ala Cys Phe Gly
 225 230 235 240

Lys Gly Thr Gln Phe Leu Ala Ala Val Leu Trp Gln Leu Asn Gly Thr
 245 250 255

Lys Ile Thr Asp Phe Gly Glu Pro Arg Ile Gln Gln Glu Glu Gly Gln
 260 265 270

Asn Gln Ser Phe Ser Asn Gly Leu Ala Cys Leu Asp Met Val Leu Arg
 275 280 285

Ile Ala Asp Val Lys Glu Glu Asp Leu Leu Leu Gln Tyr Asp Cys Leu

-continued

290	295	300
-----	-----	-----

Ala Leu Asn Leu His Gly Leu Arg Arg His Thr Val Arg Leu Ser Arg
 305 310 315 320

Lys Asn Pro Ser Lys Glu Cys Phe
 325

<210> SEQ ID NO 5
 <211> LENGTH: 556
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: SIGNAL
 <222> LOCATION: (1)..(18)
 <220> FEATURE:
 <221> NAME/KEY: CHAIN
 <222> LOCATION: (19)..(556)

<400> SEQUENCE: 5

Met Gly Phe Trp Ile Leu Ala Ile Leu Thr Ile Leu Met Tyr Ser Thr
1 5 10 15
Ala Ala Lys Phe Ser Lys Gln Ser Trp Gly Leu Glu Asn Glu Ala Leu
20 25 30
Ile Val Arg Cys Pro Arg Gln Gly Lys Pro Ser Tyr Thr Val Asp Trp
35 40 45
Tyr Tyr Ser Gln Thr Asn Lys Ser Ile Pro Thr Gln Glu Arg Asn Arg
50 55 60
Val Phe Ala Ser Gly Gln Leu Leu Lys Phe Leu Pro Ala Ala Val Ala
65 70 75 80
Asp Ser Gly Ile Tyr Thr Cys Ile Val Arg Ser Pro Thr Phe Asn Arg
85 90 95
Thr Gly Tyr Ala Asn Val Thr Ile Tyr Lys Lys Gln Ser Asp Cys Asn
100 105 110
Val Pro Asp Tyr Leu Met Tyr Ser Thr Val Ser Gly Ser Glu Lys Asn
115 120 125
Ser Lys Ile Tyr Cys Pro Thr Ile Asp Leu Tyr Asn Trp Thr Ala Pro
130 135 140
Leu Glu Trp Phe Lys Asn Cys Gln Ala Leu Gln Gly Ser Arg Tyr Arg
145 150 155 160
Ala His Lys Ser Phe Leu Val Ile Asp Asn Val Met Thr Glu Asp Ala
165 170 175
Gly Asp Tyr Thr Cys Lys Phe Ile His Asn Glu Asn Gly Ala Asn Tyr
180 185 190
Ser Val Thr Ala Thr Arg Ser Phe Thr Val Lys Asp Glu Gln Gly Phe
195 200 205
Ser Leu Phe Pro Val Ile Gly Ala Pro Ala Gln Asn Glu Ile Lys Glu
210 215 220
Val Glu Ile Gly Lys Asn Ala Asn Leu Thr Cys Ser Ala Cys Phe Gly
225 230 235 240
Lys Gly Thr Gln Phe Leu Ala Ala Val Leu Trp Gln Leu Asn Gly Thr
245 250 255
Lys Ile Thr Asp Phe Gly Glu Pro Arg Ile Gln Gln Glu Glu Gly Gln
260 265 270
Asn Gln Ser Phe Ser Asn Gly Leu Ala Cys Leu Asp Met Val Leu Arg
275 280 285

-continued

Ile	Ala	Asp	Val	Lys	Glu	Glu	Asp	Leu	Leu	Gln	Tyr	Asp	Cys	Leu	290	295	300	
Ala	Leu	Asn	Leu	His	Gly	Leu	Arg	Arg	His	Thr	Val	Arg	Leu	Ser	Arg	305	310	315
Lys	Asn	Pro	Ile	Asp	His	His	Ser	Ile	Tyr	Cys	Ile	Ile	Ala	Val	Cys	325	330	335
Ser	Val	Phe	Leu	Met	Leu	Ile	Asn	Val	Leu	Val	Ile	Ile	Leu	Lys	Met	340	345	350
Phe	Trp	Ile	Glu	Ala	Thr	Leu	Leu	Trp	Arg	Asp	Ile	Ala	Lys	Pro	Tyr	355	360	365
Lys	Thr	Arg	Asn	Asp	Gly	Lys	Leu	Tyr	Asp	Ala	Tyr	Val	Val	Tyr	Pro	370	375	380
Arg	Asn	Tyr	Lys	Ser	Ser	Thr	Asp	Gly	Ala	Ser	Arg	Val	Glu	His	Phe	385	390	395
Val	His	Gln	Ile	Leu	Pro	Asp	Val	Leu	Glu	Asn	Lys	Cys	Gly	Tyr	Thr	405	410	415
Leu	Cys	Ile	Tyr	Gly	Arg	Asp	Met	Leu	Pro	Gly	Glu	Asp	Val	Val	Thr	420	425	430
Ala	Val	Glu	Thr	Asn	Ile	Arg	Lys	Ser	Arg	Arg	His	Ile	Phe	Ile	Leu	435	440	445
Thr	Pro	Gln	Ile	Thr	His	Asn	Lys	Glu	Phe	Ala	Tyr	Glu	Gln	Glu	Val	450	455	460
Ala	Leu	His	Cys	Ala	Leu	Ile	Gln	Asn	Asp	Ala	Lys	Val	Ile	Leu	Ile	465	470	475
Glu	Met	Glu	Ala	Leu	Ser	Glu	Leu	Asp	Met	Leu	Gln	Ala	Glu	Ala	Leu	485	490	495
Gln	Asp	Ser	Leu	Gln	His	Leu	Met	Lys	Val	Gln	Gly	Thr	Ile	Lys	Trp	500	505	510
Arg	Glu	Asp	His	Ile	Ala	Asn	Lys	Arg	Ser	Leu	Asn	Ser	Lys	Phe	Trp	515	520	525
Lys	His	Val	Arg	Tyr	Gln	Met	Pro	Val	Pro	Ser	Lys	Ile	Pro	Arg	Lys	530	535	540
Ala	Ser	Ser	Leu	Thr	Pro	Leu	Ala	Ala	Gln	Lys	Gln					545	550	555

What is claimed is:

1. A method of modulating an immune disorder or condition, comprising inhibiting IL-33 signal transduction through ST2 and IL-1RAcP by administering to a subject in need thereof an effective amount of:

- a) an antagonist of IL-33 binding to a complex of ST2 and IL-1RAcP; or
- b) an antagonist of IL-1RAcP binding to a complex of IL-33 and ST2.

2. The method of claim 1, wherein the immune disorder or condition is selected from the group consisting of an innate response, asthma, an allergy, multiple sclerosis, inflammatory bowel disorder, arthritis, an infection, cancer, and a tumor.

3. The method of claim 2, wherein the infection is selected from the group consisting of an intracellular pathogen, a bacterium, a parasite and a virus.

4. The method of claim 3, wherein the infection is an intracellular pathogen selected from the group consisting of *Leishmania* sp., *Mycobacterium* sp., *Listeria* sp., *Toxoplasma* sp., *Schistosoma* sp.

5. The method of claim 1, wherein the immune disorder or condition comprises:

- a) a T_H1 -type response; or
- b) a T_H2 -type response.

6. The method of claim 2, wherein the arthritis is selected from the group consisting of rheumatoid arthritis, osteoarthritis, and psoriatic arthritis.

7. The method of claim 1, wherein the antagonist comprises an antibody or a fragment thereof that specifically binds to:

- a) IL-33;
- b) IL-1RAcP;
- c) ST2;
- d) a complex of ST2 and IL-1RAcP;
- e) a complex of IL-33 and ST2; or
- f) a complex of IL-33, ST2 and IL-1RAcP.

8. The method of claim 7, wherein the antibody or fragment thereof does not bind to ST2 alone and does not bind to IL-33 alone.

9. The method of claim 7, wherein the antibody or fragment thereof is a humanized antibody or human antibody.

10. The method of claim 7, wherein the antibody or fragment thereof is a fragment selected from the group consisting of a Fab, an Fv fragment, and an F(ab')₂ fragment.

11. A method of modulating blood cell counts, comprising inhibiting IL-33 signal transduction through ST2 and IL-1RAcP by administering to a subject in need thereof an effective amount of:

- a) an antagonist of IL-33 binding to a complex of ST2 and IL-1RAcP; or
- b) an antagonist of IL-1RAcP binding to a complex of IL-33 and ST2.

12. The method of claim 11, wherein the antagonist increases the count of platelets.

13. The method of claim 11, wherein the antagonist decreases the count of one or more of total white blood cells, neutrophils, lymphocytes, and eosinophils.

14. The method of claim 11, wherein the antagonist comprises an antibody or a fragment thereof that specifically binds to:

- a) IL-33;
- b) IL-1RAcP;
- c) ST2;
- d) a complex of ST2 and IL-1RAcP;
- e) a complex of IL-33 and ST2; or
- f) a complex of IL-33, ST2 and IL-1RAcP.

15. The method of claim 14, wherein the antibody or fragment thereof is a humanized antibody or human antibody.

16. The method of claim 14, wherein the antibody or fragment thereof is a fragment selected from the group consisting of a Fab, an Fv fragment, and an F(ab')₂ fragment.

17. An isolated and purified complex of ST2 and IL-1RAcP.

18. The isolated and purified complex of claim 17, wherein ST2 and IL-1RAcP are human ST2 and human IL-1RAcP, respectively.

19. The isolated and purified complex of claim 18, further comprising human IL-33.

20. An in vitro method of determining whether a test compound is an antagonist of i) IL-33 binding to a complex of ST2 and IL-1RAcP, or ii) IL-1RAcP binding to a complex of IL-33 and ST2, comprising an assay selected from the group consisting of:

- a) an NF-κB-dependent reporter gene expression assay;
- b) an MyD88 IRAK, IRAK4 or TRAF6 recruitment assay;
- c) an Erk1/2, p38, IκBα or JNK phosphorylation assay;
- d) an NF-κB, Erk1/2 or p38 phosphorylation assay in cells that naturally express ST2;
- e) an IL-13, IL-6 or IL-5 expression assay; and
- f) an IL-6 production assay in mouse mast cell line WTMC; wherein the test compound is determined to be an antagonist if it reduces the activity of IL-33 in the assay when compared to an assay run without the test compound.

* * * * *

专利名称(译)	调节il-33活性的方法		
公开(公告)号	US20120207752A1	公开(公告)日	2012-08-16
申请号	US13/456071	申请日	2012-04-25
[标]申请(专利权)人(译)	先灵葆雅有限公司		
申请(专利权)人(译)	Schering Corporation的		
当前申请(专利权)人(译)	Schering Corporation的		
[标]发明人	CHACKERIAN ALISSA A KASTELEIN ROBERT A		
发明人	CHACKERIAN, ALISSA A. KASTELEIN, ROBERT A.		
IPC分类号	A61K39/395 G01N33/53 A61P35/00 A61P25/00 A61P19/02 A61P11/06 A61P37/08 A61P27/02 A61P29/00 A61P31/04 A61P33/00 A61P31/12 A61P33/02 A61P33/12 C07K17/02		
CPC分类号	C07K14/7155 G01N33/6869 Y10S514/885 A61K39/3955 C12Q1/6897 G01N2500/00 A61P11/06 A61P19/02 A61P25/00 A61P27/02 A61P29/00 A61P31/04 A61P31/12 A61P33/00 A61P33/02 A61P33/12 A61P35/00		
优先权	60/887257 2007-01-30 US 60/835250 2006-08-03 US 60/832256 2006-07-20 US		
外部链接	Espacenet USPTO		

摘要(译)

本文提供了调节IL-33活性的方法，例如用于治疗免疫疾病和病症的方法，以及筛选能够拮抗IL-33信号传导的化合物的方法。




Figure 1A




Figure 1B